Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?

Jesper Grau Eriksen, Pernille Lassen, Jens Overgaard

Publikation: Bidrag til tidsskriftLetterForskningpeer review

OriginalsprogEngelsk
TidsskriftLancet Oncology
Vol/bind11
Udgave nummer4
Sider (fra-til)312-3
Antal sider2
ISSN1470-2045
DOI
StatusUdgivet - apr. 2010

Citer dette

Eriksen, Jesper Grau ; Lassen, Pernille ; Overgaard, Jens. / Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?. I: Lancet Oncology. 2010 ; Bind 11, Nr. 4. s. 312-3.
@article{c1c3aef050f911df937d000ea68e967b,
title = "Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?",
keywords = "Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Biological Markers, Combined Modality Therapy, Head and Neck Neoplasms, Humans, Male, Neoplasm Proteins, Papillomavirus Infections, Patient Selection",
author = "Eriksen, {Jesper Grau} and Pernille Lassen and Jens Overgaard",
note = "Paper id:: 20359659",
year = "2010",
month = "4",
doi = "10.1016/S1470-2045(10)70035-8",
language = "English",
volume = "11",
pages = "312--3",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "TheLancet Publishing Group",
number = "4",

}

Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab? / Eriksen, Jesper Grau; Lassen, Pernille; Overgaard, Jens.

I: Lancet Oncology, Bind 11, Nr. 4, 04.2010, s. 312-3.

Publikation: Bidrag til tidsskriftLetterForskningpeer review

TY - JOUR

T1 - Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?

AU - Eriksen, Jesper Grau

AU - Lassen, Pernille

AU - Overgaard, Jens

N1 - Paper id:: 20359659

PY - 2010/4

Y1 - 2010/4

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antineoplastic Agents

KW - Biological Markers

KW - Combined Modality Therapy

KW - Head and Neck Neoplasms

KW - Humans

KW - Male

KW - Neoplasm Proteins

KW - Papillomavirus Infections

KW - Patient Selection

U2 - 10.1016/S1470-2045(10)70035-8

DO - 10.1016/S1470-2045(10)70035-8

M3 - Letter

VL - 11

SP - 312

EP - 313

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 4

ER -